- Home
- REGN
as 07-08-2024 4:00pm EST
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | TARRYTOWN |
| Market Cap: | 112.8B | IPO Year: | 1991 |
| Target Price: | $1021.42 | AVG Volume (30 days): | 467.9K |
| Analyst Decision: | Buy | Number of Analysts: | 24 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 33.86 | EPS Growth: | -7.96 |
| 52 Week Low/High: | $688.52 - $1081.17 | Next Earning Date: | 08-01-2024 |
| Revenue: | $13,100,100,000 | Revenue Growth: | 5.90% |
| Revenue Growth (this year): | 7.52% | Revenue Growth (next year): | 8.16% |
Stock Insider Trading Activity of Regeneron Pharmaceuticals Inc. (REGN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| McCourt Marion | REGN | EVP Commercial | Jul 1 '24 | Sell | $1,047.11 | 1,137 | $1,190,564.07 | 12,931 | SEC Form 4 |
| SCHLEIFER LEONARD S | REGN | Bd. Co-Chair, President & CEO | Jun 6 '24 | Sell | $1,015.02 | 787 | $798,820.74 | 64,198 | SEC Form 4 |
| Bassler Bonnie L | REGN | Director | Jun 5 '24 | Sell | $1,011.00 | 827 | $836,097.00 | 1,382 | SEC Form 4 |
| McCourt Marion | REGN | EVP Commercial | Jun 3 '24 | Sell | $980.16 | 1,138 | $1,115,422.08 | 12,931 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jun 3 '24 | Sell | $979.40 | 2 | $1,958.80 | 18,080 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jun 3 '24 | Sell | $980.16 | 3 | $2,940.48 | 18,077 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jun 3 '24 | Sell | $981.95 | 3 | $2,945.85 | 18,074 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jun 3 '24 | Sell | $982.99 | 1 | $982.99 | 18,073 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jun 3 '24 | Sell | $984.52 | 2 | $1,969.04 | 18,071 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jun 3 '24 | Sell | $988.66 | 2 | $1,977.32 | 18,069 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jun 3 '24 | Sell | $990.74 | 4 | $3,962.96 | 18,065 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jun 3 '24 | Sell | $992.19 | 7 | $6,945.33 | 18,058 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jun 3 '24 | Sell | $993.20 | 12 | $11,918.40 | 18,046 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jun 3 '24 | Sell | $994.25 | 5 | $4,971.25 | 18,041 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jun 3 '24 | Sell | $995.76 | 6 | $5,974.56 | 18,035 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jun 3 '24 | Sell | $996.83 | 12 | $11,961.96 | 18,023 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jun 3 '24 | Sell | $997.76 | 15 | $14,966.40 | 18,008 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jun 3 '24 | Sell | $998.44 | 14 | $13,978.16 | 17,994 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jun 3 '24 | Sell | $999.43 | 7 | $6,996.01 | 17,987 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jun 3 '24 | Sell | $1,000.04 | 5 | $5,000.20 | 17,982 | SEC Form 4 |
| BROWN MICHAEL S | REGN | Director | May 28 '24 | Sell | $974.86 | 1,172 | $1,142,535.92 | 1,382 | SEC Form 4 |
| LAROSA JOSEPH J | REGN | EVP General Counsel and Secret | May 21 '24 | Sell | $994.90 | 1,865 | $1,855,488.50 | 34,678 | SEC Form 4 |
| SCHLEIFER LEONARD S | REGN | Bd. Co-Chair, President & CEO | May 17 '24 | Sell | $979.22 | 22,687 | $22,215,564.14 | 467,020 | SEC Form 4 |
| SCHLEIFER LEONARD S | REGN | Bd. Co-Chair, President & CEO | May 17 '24 | Sell | $980.07 | 143 | $140,150.01 | 466,877 | SEC Form 4 |
| YANCOPOULOS GEORGE | REGN | Bd. Co-Chair, President & CSO | May 16 '24 | Sell | $967.40 | 907 | $877,431.80 | 835,476 | SEC Form 4 |
Latest Regeneron Pharmaceuticals Inc. News
REGN Breaking Stock News: Dive into REGN Ticker-Specific Updates for Smart Investing
Motley Fool
9 hours ago
3 No-Brainer Stocks to Buy in July
Investor's Business Daily
3 days ago
Swing Trading Regeneron Stock Shows How To Bob And Weave
Pharmaceutical Technology
3 days ago
Dupixent “addresses current gap” in COPD biologics landscape
Benzinga
5 days ago
Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
Zacks
5 days ago
Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
MT Newswires
6 days ago
Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval
GlobeNewswire
6 days ago
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
GuruFocus.com
6 days ago
Insider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)
Share on Social Networks:
Disclaimer
The information presented on this page, "REGN Regeneron Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.